| A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC) (NCT03083041) | Jiangsu HengRui Medicine Co., Ltd. | 2017-03-13 |
| The Watch the Spot Trial (NCT02623712) | Kaiser Permanente | 2017-03-06 |
| Prognostic Value of PD-L1 in NSCLC (NCT03078959) | Fondazione Ricerca Traslazionale | 2017-03-03 |
| Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer) (NCT03053297) | AstraZeneca | 2017-03-01 |
| Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA (NCT02811354) | National University Hospital, Singapore | 2017-02-24 |
| Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC (NCT03044626) | AIO-Studien-gGmbH | 2017-02-10 |
| Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer (NCT03030131) | Intergroupe Francophone de Cancerologie Thoracique | 2017-01-12 |
| Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2 (NCT02733159) | University of Birmingham | 2017-01-04 |
| Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer (NCT03092986) | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 2017-01-01 |
| NSE/Alb as a Prognostic Biomarker for Lung Cancer (NCT03724604) | First Affiliated Hospital Xi'an Jiaotong University | 2017-01-01 |
| Correlation of Metabolic Imaging With Immune Markers in NSCLC Candidate to Immunotherapy. (NCT03563482) | Istituto Clinico Humanitas | 2017-01-01 |
| A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NCT03023423) | Janssen Research & Development, LLC | 2016-12-23 |
| Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer (NCT02904954) | Weill Medical College of Cornell University | 2016-12-02 |
| Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer (NCT02410603) | Mayo Clinic | 2016-12-01 |
| Personalized DC Vaccine for Lung Cancer (NCT02956551) | Sichuan University | 2016-11-30 |
| Real World Data on Gi(l)Otrif® Dose Adjustment (NCT02751879) | Boehringer Ingelheim | 2016-11-24 |
| Merestinib In Non-Small Cell Lung Cancer And Solid Tumors (NCT02920996) | Dana-Farber Cancer Institute | 2016-11-11 |
| Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer (NCT02954991) | Mirati Therapeutics Inc. | 2016-11-07 |
| High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC (NCT02960607) | Chinese Academy of Medical Sciences | 2016-11-01 |
| Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC (NCT03001609) | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | 2016-11-01 |
| A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (NCT02826161) | Sumitomo Pharma America, Inc. | 2016-11-01 |
| Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment (NCT03053219) | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | 2016-11-01 |
| Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases (NCT02759783) | Royal Marsden NHS Foundation Trust | 2016-11-01 |
| Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma (NCT02775006) | The Netherlands Cancer Institute | 2016-10-14 |
| Study of ASN003 in Subjects With Advanced Solid Tumors (NCT02961283) | Asana BioSciences | 2016-10-01 |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer (NCT02897765) | BioNTech US Inc. | 2016-10-01 |
| Effect of Different Anesthetics on the Change of Alarmins in Lung Cancer Patients Receiving Pulmonary Lobectomy (NCT02916147) | Tianjin Medical University Cancer Institute and Hospital | 2016-10-01 |
| A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC (NCT02847377) | Centre Georges Francois Leclerc | 2016-09-27 |
| Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (NCT02909452) | Syndax Pharmaceuticals | 2016-09-20 |
| Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033) (NCT02864394) | Merck Sharp & Dohme LLC | 2016-09-07 |
| TR(ACE) Assay Clinical Specimen Study (NCT02934360) | Biological Dynamics | 2016-09-01 |
| Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors (NCT02926768) | Checkpoint Therapeutics, Inc. | 2016-09-01 |
| Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC (NCT02799862) | iOMEDICO AG | 2016-08-29 |
| Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors (NCT02897778) | Syndax Pharmaceuticals | 2016-08-24 |
| Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) (NCT02862457) | Merck Sharp & Dohme LLC | 2016-08-23 |
| Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC) (NCT02419170) | Washington University School of Medicine | 2016-07-01 |
| A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy (NCT02813785) | Hoffmann-La Roche | 2016-07-01 |
| A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (NCT02716116) | Takeda | 2016-06-16 |
| Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC (NCT02716038) | Columbia University | 2016-06-07 |
| Lung Cancer Early Molecular Assessment Trial (NCT02894853) | The Netherlands Cancer Institute | 2016-06-01 |
| MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients (NCT02574598) | Instituto Nacional de Cancerologia de Mexico | 2016-06-01 |
| Genetic Predictors of Benefit to Pembrolizumab (NCT02710396) | Columbia University | 2016-05-31 |
| PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC (NCT02777658) | AstraZeneca | 2016-05-26 |
| Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer (NCT02751385) | Boehringer Ingelheim | 2016-05-20 |
| Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients (NCT02804100) | Wenzhou Medical University | 2016-05-01 |
| Atovaquone as Tumour HypOxia Modifier (NCT02628080) | University of Oxford | 2016-05-01 |
| A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy (NCT02623595) | Wuhan University | 2016-05-01 |
| Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC) (NCT02705339) | Washington University School of Medicine | 2016-05-01 |
| Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer (NCT02743923) | The Netherlands Cancer Institute | 2016-04-01 |
| Afatinib in NSCLC With HER2 Mutation (NCT02597946) | Boehringer Ingelheim | 2016-03-18 |
| Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3) (NCT02695290) | Boehringer Ingelheim | 2016-03-17 |
| Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma (NCT02668393) | Boehringer Ingelheim | 2016-03-07 |
| The Effect on Decreasing Chemotherapeutic Toxicity and Increasing Anti-tumor Effect of Chinese Herbs Based on Syndrome Differentiation (NCT02737735) | First Affiliated Hospital, Sun Yat-Sen University | 2016-03-01 |
| Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression (NCT02919462) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2016-03-01 |
| Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings (NCT02440854) | Boehringer Ingelheim | 2016-02-16 |
| A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer (NCT02492867) | University of Michigan Rogel Cancer Center | 2016-01-14 |
| Clinical Study of Ganoderma Lucidum Spore Combined With Chemotherapy (NCT02844114) | Gao Yajie | 2016-01-01 |
| Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer (NCT02592967) | Janssen Research & Development, LLC | 2015-12-02 |
| Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer (NCT02655913) | Clifford Hospital, Guangzhou, China | 2015-12-01 |
| Efficacy and Safety Analyses of Mirtazapine in NSCLC Patients With Depression (NCT02650544) | Sun Yat-sen University | 2015-12-01 |
| Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors (NCT02537561) | Washington University School of Medicine | 2015-12-01 |
| Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance (NCT02483416) | Boehringer Ingelheim | 2015-11-19 |
| Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer (NCT02590003) | Yale University | 2015-11-01 |
| BIO 300 Non-Small Cell Lung Cancer Study (NCT02567799) | Humanetics Corporation | 2015-11-01 |
| Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT02546986) | Celgene | 2015-10-09 |
| Genomic Landscape of Ceritinib (NCT02554591) | Washington University School of Medicine | 2015-09-16 |
| SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer (NCT02562027) | Washington University School of Medicine | 2015-09-11 |
| Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older (NCT02514174) | Boehringer Ingelheim | 2015-08-18 |
| A Prospective Multi-center Phase III Randomized Controlled Trial (NCT02607592) | Sun Yat-sen University | 2015-08-01 |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers (NCT02487095) | National Cancer Institute (NCI) | 2015-07-30 |
| MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) (NCT02422381) | Providence Health & Services | 2015-07-20 |
| LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer (NCT02511288) | Centre Leon Berard | 2015-07-01 |
| Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC) (NCT02475720) | AstraZeneca | 2015-06-19 |
| Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1) (NCT02414139) | Novartis Pharmaceuticals | 2015-06-11 |
| Afatinib Genomic Landscape (NCT02491775) | Washington University School of Medicine | 2015-06-11 |
| RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) (NCT02489903) | EpicentRx, Inc. | 2015-06-01 |
| Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma (NCT02805530) | Instituto Nacional de Cancerologia de Mexico | 2015-06-01 |
| Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer (NCT02450656) | The Netherlands Cancer Institute | 2015-06-01 |
| Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI) (NCT02342353) | Washington University School of Medicine | 2015-05-18 |
| Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NCT02299141) | Washington University School of Medicine | 2015-05-07 |
| Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients (NCT02187367) | Bioven Europe | 2015-05-01 |
| Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer (NCT02448303) | Acerta Pharma BV | 2015-05-01 |
| Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer (NCT02645318) | Peking University People's Hospital | 2015-05-01 |
| Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression (NCT02431169) | Washington University School of Medicine | 2015-04-30 |
| Pazopanib in Molecularly Selected Patients With Advanced NSCLC (NCT02193152) | Washington University School of Medicine | 2015-04-27 |
| Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer (NCT02671045) | Cota Inc. | 2015-04-01 |
| Pharmacological Ascorbate for Lung Cancer (NCT02420314) | Joseph J. Cullen, MD, FACS | 2015-04-01 |
| A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (NCT02366143) | Hoffmann-La Roche | 2015-03-31 |
| Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200) (NCT02395172) | EMD Serono Research & Development Institute, Inc. | 2015-03-24 |
| VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC) (NCT02392455) | Boehringer Ingelheim | 2015-03-23 |
| Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC (NCT02343952) | Nasser Hanna, M.D. | 2015-03-09 |
| Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients (NCT03236675) | Exosome Diagnostics, Inc. | 2015-03-01 |
| Safety Study of SEA-CD40 in Cancer Patients (NCT02376699) | Seagen Inc. | 2015-02-28 |
| Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer (NCT02250326) | Celgene | 2015-01-07 |
| Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR) (NCT02332512) | Jiangsu HengRui Medicine Co., Ltd. | 2015-01-01 |
| Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy (NCT02300298) | Boehringer Ingelheim | 2014-12-24 |
| Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China (NCT02381808) | Guangdong Association of Clinical Trials | 2014-12-01 |
| Role of FDG PET, Immune and Hypoxic Marker in NSCLC (NCT02519062) | Istituto Clinico Humanitas | 2014-12-01 |
| Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS) (NCT02499614) | Fondazione Ricerca Traslazionale | 2014-12-01 |
| Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) (NCT02191891) | Boehringer Ingelheim | 2014-10-21 |